Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 4,654 Avalo Therapeutics, Inc. shares (Form 4)

Traded Jun 30, 2026 · Filed Jul 2, 2026

On Jun 30, 2026, Doyle Mittie (Chief Medical Officer) sold 4,654 Avalo Therapeutics, Inc. shares at US$20.00 for US$93,080 under a trading plan, leaving 51,776 shares. Filed Jul 2, 2026 (Form 4).

Sold
4,654 shares
Price
US$20.00
Value
US$93,080
Holding after
51,776 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Medical Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 30, 2026Common StockOption exercise2,875US$12.6554,651Direct
Jun 30, 2026Common StockOption exercise1,779US$8.0456,430Direct
Jun 30, 2026Common StockSale4,654US$20.0051,776Direct

Source

View original at SEC

Related